Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RTA 408 Lotion 0.5%, 1%, 3%
RTA 408 0.5%, 1%, 3% · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A | PLACEBO_COMPARATOR | RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days |
| Part B | EXPERIMENTAL | Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, \~100 cm2 surface area) |
| Part C | EXPERIMENTAL | 3% RTA 408 lotion applied to skin twice daily for 28 days (\~500 cm2 surface area) |
| Name | Type | Description |
|---|---|---|
| RTA 408 Lotion 0.5%, 1%, 3% | DRUG | - |
| Lotion vehicle/placebo | DRUG | - |
Inclusion Criteria: 1. Subjects must voluntarily give written informed consent and agree to comply with visit schedule including willingness to remain at the study site; 2. Subjects must be adults (male or female), ages 18 to 65, inclusive; 3. Subjects must have healthy skin on which reddening can ...
RTA 408 0.5%, 1%, and 3% are three lotion strengths of a small molecule drug candidate developed by Biogen Inc. (BIIB). They were studied in healthy adult volunteers rather than in patients with a disease, and the program is at the Phase 1 stage of clinical development.
Biogen Inc., which trades on Nasdaq under the ticker BIIB, is the developer of RTA 408 0.5%, 1%, and 3% lotion. The company sponsored the Phase 1 study of these lotion strengths in healthy volunteers in the United States.
RTA 408 0.5%, 1%, and 3% lotion are in Phase 1 development. The program has one completed Phase 1 trial, and no active trials are ongoing. The drug is investigational and has not been approved by the FDA.
RTA 408 0.5%, 1%, and 3% lotion were evaluated in the completed Phase 1 trial NCT02029716, titled RTA 408 Lotion in Healthy Volunteers. The study enrolled 109 participants in the United States, used a randomized, double-blind, placebo-controlled design, and included adults aged 18 years and older.
Yes. RTA 408 0.5%, 1%, and 3% is also known as RTA 408 Lotion 0.5%, 1%, and 3%. The two names refer to the same three lotion strengths of the investigational small molecule developed by Biogen Inc. for study in healthy volunteers.